Hostname: page-component-77f85d65b8-8wtlm Total loading time: 0 Render date: 2026-04-12T13:44:22.878Z Has data issue: false hasContentIssue false
  • English
  • Français

MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al

Published online by Cambridge University Press:  06 March 2026

Tor-Morten Kvam Open the ORCID record for Tor-Morten Kvam [Opens in a new window] ,
Ivar Walderhaug Goksøyr ,
Justyna Rog ,
Ingrid Autran ,
Mark Berthold-Losleben  and
Ole Andreas Andreassen Open the ORCID record for Ole Andreas Andreassen [Opens in a new window]
Tor-Morten Kvam*
Affiliation:
DPS Nord, Østfold Hospital Trust, Grålum, Norway Institute of Clinical Medicine, University of Oslo, Norway
Ivar Walderhaug Goksøyr
Affiliation:
DPS Nord, Østfold Hospital Trust, Grålum, Norway
Justyna Rog
Affiliation:
DPS Nord, Østfold Hospital Trust, Grålum, Norway
Ingrid Autran
Affiliation:
DPS Nord, Østfold Hospital Trust, Grålum, Norway
Mark Berthold-Losleben
Affiliation:
DPS Nord, Østfold Hospital Trust, Grålum, Norway Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway
Ole Andreas Andreassen
Affiliation:
Institute of Clinical Medicine, University of Oslo, Norway Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Norway
*
Correspondence: Tor-Morten Kvam. Email: tor-morten.kvam@so-hf.no
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Depressive disordersclinical trialspsychological medicinepsychotherapypsychopharmacology

Information

Type
Commentary
Information
The British Journal of Psychiatry , First View , pp. 1 - 2
Check for updates
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Ai, Y, Xie, J, Hou, X. MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Ai et al. Br J Psychiatry [Epub ahead of print] 10 Dec 2025. Available from: https://doi.org/10.1192/bjp.2025.10474.Google ScholarPubMed
European Medicines Agency. ICH Topic E 9 Statistical Principles for Clinical Trials . European Medicines Agency, 1998 (www.ema.europa.eu).Google Scholar
Kvam, T-M, Goksøyr, IW, Stewart, LH, Repantis, D, Røssberg, JI, Andreassen, OA. Study protocol for ‘MDMA-assisted therapy as a treatment for major depressive disorder: a proof of principle study’. Front Psychiatry 2022; 13: 954388.10.3389/fpsyt.2022.954388CrossRefGoogle ScholarPubMed
Kvam, TM, Goksoyr, IW, Rog, J, van de Vooren, IJ, Stewart, LH, Autran, I, et al. MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. Br J Psychiatry 2025; 227: 1–7.10.1192/bjp.2025.10320CrossRefGoogle ScholarPubMed
Johnson, M, Richards, W, Griffiths, R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008; 22: 603–20.10.1177/0269881108093587CrossRefGoogle ScholarPubMed

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.